Trevi Therapeutics Valuation
| TRVI Stock | USD 6.47 0.14 2.12% |
At this time, the company appears to be overvalued. Trevi Therapeutics has a current Real Value of $5.04 per share. The regular price of the company is $6.47. Our model measures the value of Trevi Therapeutics from inspecting the company fundamentals such as Shares Owned By Institutions of 82.43 %, shares outstanding of 89.37 M, and Return On Equity of -0.53 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Trevi Therapeutics' valuation include:
Overvalued
Today
Please note that Trevi Therapeutics' price fluctuation is risky at this time. Calculation of the real value of Trevi Therapeutics is based on 3 months time horizon. Increasing Trevi Therapeutics' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Trevi Therapeutics is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Trevi Stock. However, Trevi Therapeutics' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.47 | Real 5.04 | Target 9.94 | Hype 6.81 | Naive 7.7 |
The intrinsic value of Trevi Therapeutics' stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Trevi Therapeutics' stock price.
Estimating the potential upside or downside of Trevi Therapeutics helps investors to forecast how Trevi stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Trevi Therapeutics more accurately as focusing exclusively on Trevi Therapeutics' fundamentals will not take into account other important factors: When choosing an evaluation method for Trevi Therapeutics, ensure it is appropriate for the firm given its current financial situation and market classification. If more than one evaluation category is relevant, we suggest using all methods to arrive at a better estimate.
Trevi Therapeutics Cash |
|
Trevi Valuation Trend
Trevi Therapeutics' real value analysis enables investors to forecast the earnings more efficiently. Using both Trevi Therapeutics' enterprise value as well as its market capitalization is the best way to gauging the value of the company and is usually enough for investors to make market timing decisions.
Trevi Therapeutics Total Value Analysis
Trevi Therapeutics is at this time anticipated to have valuation of 501.99 M with market capitalization of 590.71 M, debt of 1.03 M, and cash on hands of 77.86 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Trevi Therapeutics fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
501.99 M | 590.71 M | 1.03 M | 77.86 M |
Trevi Therapeutics Asset Utilization
One of the ways to look at asset utilization of Trevi is to check how much profit was generated for every dollar of assets it reports. Trevi Therapeutics has a negative utilization of assets of -0.32 %, losing $0.003215 for each dollar of assets held by the company. Inadequate asset utilization indicates the company is being less effective with each dollar of assets it has. In other words, asset utilization of Trevi Therapeutics shows how discouraging it operates for each dollar spent on its assets.Trevi Therapeutics Ownership Allocation
Trevi Therapeutics shows a total of 89.37 Million outstanding shares. The majority of Trevi Therapeutics outstanding shares are owned by institutional holders. These institutional investors are usually referred to as non-private investors looking to take positions in Trevi Therapeutics to benefit from reduced commissions. Consequently, institutions are subject to a different set of regulations than regular investors in Trevi Therapeutics. Please pay attention to any change in the institutional holdings of Trevi Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Trevi Therapeutics Profitability Analysis
Net Loss for the year was (47.91 M) with profit before overhead, payroll, taxes, and interest of 0.About Trevi Therapeutics Valuation
An absolute valuation paradigm, as applied to Trevi Stock, attempts to find the value of Trevi Therapeutics based on its fundamental and basic technical indicators. By analyzing Trevi Therapeutics's financials, quarterly and monthly indicators, and their related drivers, such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Trevi Therapeutics's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Trevi Therapeutics. We calculate exposure to Trevi Therapeutics's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Trevi Therapeutics's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -110.7 K | -105.2 K |
Trevi Therapeutics Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 101 M |
Trevi Therapeutics Current Valuation Indicators
Valuation refers to the process of determining the present value of Trevi Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Trevi we look at many different elements of the entity such as Trevi's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Trevi Therapeutics, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Trevi Therapeutics' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Trevi Therapeutics' worth.Complementary Tools for Trevi Stock analysis
When running Trevi Therapeutics' price analysis, check to measure Trevi Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Trevi Therapeutics is operating at the current time. Most of Trevi Therapeutics' value examination focuses on studying past and present price action to predict the probability of Trevi Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Trevi Therapeutics' price. Additionally, you may evaluate how the addition of Trevi Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |